Hypoglycemic composition and application thereof
By using traditional Chinese medicinal herbs such as sea buckthorn to prepare a hypoglycemic composition, combined with low-temperature fermentation and enzymatic hydrolysis technology, the problem of Western medicine only treating the symptoms and not the root cause has been solved. This has achieved safe and effective blood waste removal and blood sugar regulation, significantly improving patients' health indicators.
Patent Information
- Application Number
- CN202411055712.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-15
AI Technical Summary
While existing Western medicines can quickly lower blood lipids and blood sugar, they only treat the symptoms and not the root cause, and they can cause serious damage to the liver and kidneys. The development of traditional Chinese medicine hypoglycemic combinations has not yet been effectively solved.
Using sea buckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, mulberry, sorbitol, magnesium stearate, and probiotics as raw materials, a hypoglycemic composition is prepared through low-temperature fermentation and enzymatic hydrolysis technology. It cleanses blood waste, toxins, and visceral fat, improves microcirculation, and regulates blood lipids, blood pressure, and blood sugar.
It fundamentally improves blood quality, lowers blood lipids, blood pressure and blood sugar, enhances immunity, and improves cardiopulmonary function, without the toxic side effects of Western medicine and hormones, and significantly improves the course of diabetes in patients.
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicines, and more particularly to a hypoglycemic composition and application thereof. Background Art
[0002] Two thousand years ago, Chinese medicine had the idea that "impurities in the blood are the source of all diseases". Only healthy blood can bring a good physique. All diseases are caused by blood, for example: hyperlipidemia, hypertension, hyperglycemia, diabetes, hyperuricemia, gout, myocardial infarction, cerebral infarction, cerebral hemorrhage, atherosclerosis, vascular plaques, fatty liver, heart disease and other chronic diseases and metabolic syndrome are all due to excessive blood waste and fat blocking the internal organs, causing abnormal or disordered metabolic function. Visceral fat mainly exists in the internal organs in the abdominal cavity. Visceral fat is extremely harmful to health. Excessive visceral fat will cause the occurrence of various symptoms.
[0003] As blood lipids increase, there will be a large amount of lipid waste, toxins and heavy metals in the blood. If these blood wastes are not cleaned up for many years, they will form atherosclerosis, which will lead to the occurrence of various chronic diseases. When blood wastes enter the microcirculation system of arterial capillaries, the microcirculation system will be blocked.
[0004] The main lipid-lowering drugs on the market include statins, fibrates and other Western medicines. These Western medicines have rapid effects, but they only treat the symptoms and not the root cause, and can cause great damage to the liver and kidneys.
[0005] Western medicine temporarily lowered blood lipids, but did not fundamentally solve the problem. After stopping the medication, many patients' indicators quickly rebounded, and this repeated cycle caused damage to organs such as the liver and kidneys.
[0006] Therefore, whether it is possible to provide a hypoglycemic composition based on traditional Chinese medicine is an urgent problem to be solved by those skilled in the art. Summary of the invention
[0007] In view of this, the present invention provides a hypoglycemic composition and application thereof.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] A hypoglycemic composition comprises seabuckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, mulberry, sorbitol, magnesium stearate and probiotics.
[0010] Preferably, the ingredients include, by mass: 3-5 parts of seabuckthorn, 15-20 parts of Jerusalem artichoke, 10-15 parts of ginseng, 5-10 parts of bitter melon, 3-5 parts of polygonatum, 2-4 parts of yam, 5-8 parts of kudzu root, 5-10 parts of wolfberry, 5-10 parts of mulberry, 2-4 parts of sorbitol, 1-3 parts of magnesium stearate and 3-5 parts of probiotics.
[0011] Preferred: comprising, by mass: 4 parts of seabuckthorn, 18 parts of Jerusalem artichoke, 13 parts of ginseng, 7 parts of bitter melon, 4 parts of polygonatum, 3 parts of yam, 7 parts of kudzu root, 10 parts of wolfberry, 8 parts of mulberry, 3 parts of sorbitol, 2 parts of magnesium stearate and 4 parts of probiotics.
[0012] The present invention also provides a method for preparing any of the above-mentioned hypoglycemic compositions, comprising the following steps:
[0013] (1) seabuckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, and mulberry are mixed and crushed to obtain a base material;
[0014] (2) adding water, amylase, lipase and cellulase to the base material for enzymolysis and then killing the enzymes to obtain an enzymolyzate;
[0015] (3) adding the enzymatic hydrolysate to probiotics for low-temperature fermentation to obtain a fermentation material;
[0016] (4) Add sorbitol to the fermented material, stir evenly and then dry; finally add magnesium stearate, mix evenly and then press.
[0017] Preferably: Step (1) crushing: passing through a 500 mesh sieve.
[0018] Preferably: the mass ratio of the base material to water in step (2) is 1:7-9; the mass ratio of the base material to amylase, lipase and cellulase is 100:1:1-2:1-2; enzymolysis: 25-40°C, enzymolysis time 1-2d; enzyme inactivation temperature: 100°C.
[0019] Preferably: step (3) low temperature fermentation: 15-20°C, fermentation time 2-3 days.
[0020] Preferably: Step (4) drying: the water content is less than 10%.
[0021] The present invention also provides application of any of the above hypoglycemic compositions in pharmaceuticals and foods.
[0022] Preferably, the drug is in the form of tablets or pills.
[0023] It can be seen from the above technical solutions that, compared with the prior art, the present invention discloses a hypoglycemic composition and its application, and the technical effects achieved are:
[0024] 1. Using Chinese medicinal materials on the list of medicine and food as raw materials, through low-temperature fermentation and enzymatic hydrolysis technology, the original efficacy of Chinese medicine is improved several times;
[0025] 2. The whole formula is based on the theory of clearing, regulating, supplementing and nourishing; it nourishes the internal organs, speeds up metabolism, opens up the upper, middle and lower burners, lowers blood lipids, blood pressure, uric acid and blood sugar by clearing blood waste, toxins and visceral fat, dissolving blood clots and unblocking microcirculation blockages.
[0026] 3. No western medicine or hormone ingredients are added, and there are no toxic side effects.
[0027] 4. Patients who take the medicine for more than one month will experience lower blood sugar levels and ruddy complexion, increased appetite, smooth intestines, vigorous energy, enhanced cardiopulmonary function, improved varicose veins, and improved immunity. Patients with a longer course of diabetes will generally see significant improvement in four months. DETAILED DESCRIPTION
[0028] The following will be described clearly and completely in conjunction with the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] The embodiment of the invention discloses a hypoglycemic composition and application thereof.
[0030] Dosage: Two or three times a day, total daily amount 3-8g, take about half an hour after meal. One month is one cycle.
[0031] It is necessary to correspond to the actual condition of the patient and adjust the actual dosage. People with severe liver damage, poor metabolic function, serious underlying diseases and the elderly should be arranged to take a reduced dose as appropriate. People with a history of cardiovascular and cerebrovascular bleeding must recover for one year before taking it; it is recommended to avoid alcohol, spicy food, and greasy food. It is advisable to drink tea two hours after taking this product; drink more warm water, maintain a light diet, increase exercise, ensure adequate sleep and a healthy lifestyle. Unsuitable groups: pregnant women, children and adolescents under the age of fourteen, those with pacemakers, stents, and heart bypass surgery. Do not take it at the same time as statins, fibrates, and enteric-coated aspirin tablets.
[0032] The biochemical detection methods not mentioned in the examples are all summarized from the patients' test report data in the hospital.
[0033] Example 1
[0034] A hypoglycemic composition comprises, by mass, 3 parts of seabuckthorn, 15 parts of Jerusalem artichoke, 10 parts of ginseng, 5 parts of bitter melon, 3 parts of polygonatum, 2 parts of yam, 5 parts of kudzu root, 5 parts of wolfberry, 5 parts of mulberry, 2 parts of sorbitol, 1 part of magnesium stearate and 3 parts of probiotics.
[0035] The preparation method comprises the following steps:
[0036] (1) seabuckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, and mulberry are mixed and crushed to obtain a base material;
[0037] (2) adding water, amylase, lipase and cellulase to the base material for enzymolysis and then killing the enzymes to obtain an enzymolyzate;
[0038] (3) adding the enzymatic hydrolysate to probiotics for low-temperature fermentation to obtain a fermentation material;
[0039] (4) Add sorbitol to the fermented material, stir evenly and then dry; finally add magnesium stearate, mix evenly and then press.
[0040] To further optimize the technical solution: Step (1) Crushing: Pass through a 500-mesh sieve.
[0041] To further optimize the technical scheme: in step (2), the mass ratio of base material to water is 1:7; the mass ratio of base material to amylase, lipase and cellulase is 100:1:1:1; enzymolysis: 25°C, enzymolysis time 1d; enzyme inactivation temperature: 100°C.
[0042] To further optimize the technical solution: Step (3) low temperature fermentation: 15°C, fermentation time 2d.
[0043] To further optimize the technical solution: Step (4) Drying: The water content is less than 10%.
[0044] To further optimize the technical solution: the dosage form of the medicine is pills.
[0045] Example 2
[0046] A hypoglycemic composition comprises, by weight (g), 4 parts of seabuckthorn, 18 parts of Jerusalem artichoke, 13 parts of ginseng, 7 parts of bitter melon, 4 parts of polygonatum, 3 parts of yam, 7 parts of kudzu root, 10 parts of wolfberry, 8 parts of mulberry, 3 parts of sorbitol, 2 parts of magnesium stearate and 4 parts of probiotics.
[0047] The preparation method comprises the following steps:
[0048] (1) seabuckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, and mulberry are mixed and crushed to obtain a base material;
[0049] (2) adding water, amylase, lipase and cellulase to the base material for enzymolysis and then killing the enzymes to obtain an enzymolyzate;
[0050] (3) adding the enzymatic hydrolysate to probiotics for low-temperature fermentation to obtain a fermentation material;
[0051] (4) Add sorbitol to the fermented material, stir evenly and then dry; finally add magnesium stearate, mix evenly and then press.
[0052] To further optimize the technical solution: Step (1) Crushing: Pass through a 500-mesh sieve.
[0053] To further optimize the technical solution: in step (2), the mass ratio of base material to water is 1:8; the mass ratio of base material to amylase, lipase and cellulase is 100:1:2:2; enzymolysis: 35°C, enzymolysis time 2d; enzyme inactivation temperature: 100°C.
[0054] To further optimize the technical solution: Step (3) low-temperature fermentation: 17°C, fermentation time 2d.
[0055] To further optimize the technical solution: Step (4) Drying: The water content is less than 10%.
[0056] To further optimize the technical solution: the dosage form of the medicine is tablets.
[0057] Example 3
[0058] A hypoglycemic composition comprises, by weight, 5 parts of seabuckthorn, 20 parts of Jerusalem artichoke, 15 parts of ginseng, 10 parts of bitter melon, 5 parts of polygonatum, 4 parts of yam, 8 parts of kudzu root, 10 parts of wolfberry, 10 parts of mulberry, 4 parts of sorbitol, 3 parts of magnesium stearate and 5 parts of probiotics.
[0059] The preparation method comprises the following steps:
[0060] (1) seabuckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, and mulberry are mixed and crushed to obtain a base material;
[0061] (2) adding water, amylase, lipase and cellulase to the base material for enzymolysis and then killing the enzymes to obtain an enzymolyzate;
[0062] (3) adding the enzymatic hydrolysate to probiotics for low-temperature fermentation to obtain a fermentation material;
[0063] (4) Add sorbitol to the fermented material, stir evenly and then dry; finally add magnesium stearate, mix evenly and then press.
[0064] To further optimize the technical solution: Step (1) Crushing: Pass through a 500-mesh sieve.
[0065] To further optimize the technical solution: in step (2), the mass ratio of base material to water is 1:9; the mass ratio of base material to amylase, lipase and cellulase is 100:1:1:2; enzymolysis: 40°C, enzymolysis time 2d; enzyme inactivation temperature: 100°C.
[0066] To further optimize the technical solution: Step (3) low-temperature fermentation: 20°C, fermentation time 2d.
[0067] To further optimize the technical solution: Step (4) Drying: The water content is less than 10%.
[0068] Preferably, the dosage form of the drug is a tablet.
[0069] Technical effect verification
[0070] 1Reverse liver damage indicators:
[0071] Control group: 5 patients who did not take any medication;
[0072] Experimental group: 4 patients taking the hypoglycemic composition prepared in Example 2;
[0073] Before the experiment, screening for underlying diseases was performed, and patients with no underlying medical history and similar abnormal indicators (all 1.5 to 2.5 times higher than the reference value) were selected for inclusion in the group. Aspartate aminotransferase, alanine aminotransferase, and glutamyl transpeptidase were used as indicators. The experiment lasted for one month, and the changes in the indicators were compared.
[0074] The experimental results showed that: in the control group, there was no significant change;
[0075] In the experimental group, the levels of alanine aminotransferase in 3 patients dropped to the normal range, and that of 1 patient remained above the standard but showed a downward trend.
[0076] 2. Regulate blood lipids in four ways
[0077] Control group: 3 patients who did not take any medication;
[0078] Experimental group: 3 patients taking the hypoglycemic composition prepared in Example 2;
[0079] Total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were used as indicators. The experiment lasted for one month and the changes in the indicators were compared.
[0080] The experimental results show that compared with the control group, the total cholesterol, triglycerides, and low-density lipoprotein cholesterol in the experimental group decreased significantly, among which one patient in the experimental group had a direct reversal of the index, while the high-density lipoprotein cholesterol in the experimental group increased (an indicator of patients' resistance to the risk of cardiovascular and cerebrovascular diseases, the higher the better within a certain range). This shows that the present invention has a bidirectional regulatory effect.
[0081] 3. Atherosclerosis Index
[0082] 7 patients with a range of 4.4 to 4.8 were screened
[0083] Control group: 4 patients who did not take any medication;
[0084] Experimental group: 3 patients taking the hypoglycemic composition prepared in Example 2;
[0085] The experiment lasted for two months, and the changes in indicators were compared.
[0086] The experimental results showed that the indexes of the three patients in the experimental group all dropped below 4, while in the control group, three patients showed no significant changes and one patient showed an increase. This shows that the present invention has a reversal effect on atherosclerosis and cardiovascular and cerebrovascular diseases. As the conditioning progresses, the blood vessels gradually soften, allowing the blood vessels to regain elasticity, and completely reverse atherosclerosis. It has a very good effect on the prevention of cardiovascular and cerebrovascular diseases and myocardial infarction and cerebral infarction.
[0087] In addition, when conducting medication visits for other more serious patients (plaques that have already formed in the blood vessels), the summary results show that soft plaques that are generally smaller than 5mm are likely to disappear in about a month (the results of the patient's hospital reexamination in about a month indicate this). As for mixed plaques: the plaques have been formed for a long time and have been transformed from soft plaques to mixed plaques. Generally, mixed plaques within 8mm will disappear in about three months (the results of the patient's hospital reexamination in about three months indicate this).
[0088] 4. Blood Pressure
[0089] Blood pressure indicators of patients with hypertension caused by vascular congestion and arteriosclerosis generally stabilize within a month (a total of 13 patients were tracked), and physical symptoms (such as dizziness and headache) basically disappear. With the gradual improvement of the cardiovascular and metabolic systems, hypertension is reversed from the root.
[0090] 5. Patients with high uric acid and gout
[0091] Generally, it will gradually stabilize in one month (a total of 4 patients were followed up). Among them, the uric acid indicators of 3 patients with simple hyperuricemia steadily decreased and returned to normal as the metabolic system gradually improved.
[0092] 6. High blood sugar
[0093] Control group: 4 patients who did not take any medication;
[0094] Experimental group: 4 patients taking the hypoglycemic composition prepared in Example 2;
[0095] All patients included in the group were simple hyperglycemia patients (blood sugar level 11.5-12mmol / L 2 hours after meal). Blood sugar indexes were used for comparison. During the 4-month experimental period, there was no significant change in blood sugar levels in the 3 patients in the control group, and 1 patient had a slight increase. However, all patients in the experimental group had a decrease in blood sugar levels, with the index reaching 6.4-7.3mmol / L, almost returning to normal, which was a significant improvement.
[0096] 7 Other specific case records and efficacy:
[0097] Case 1: fasting blood sugar was 14.5, and after taking the hypoglycemic composition prepared in Example 2 of the present invention for 3 weeks, blood sugar returned to fasting blood sugar 7.8;
[0098] Case 2: Blood sugar level was 14.6 2 hours after meal. After taking the hypoglycemic composition prepared in Example 2 of the present invention for 9 days, blood sugar level dropped to 9.4 2 hours after meal.
[0099] Case 3: fasting blood sugar was 14.9. After taking the hypoglycemic composition prepared in Example 2 of the present invention for one week, the fasting blood sugar dropped to 7.1; the symptoms of blurry eyes and numbness in legs and feet were alleviated;
[0100] Case 4: The patient was nearly 70 years old, with a blood sugar level of 15 2 hours after a meal. After taking the hypoglycemic composition prepared in Example 2 of the present invention, the blood sugar level dropped to 9.8 2 hours after a meal after one week.
[0101] Case 5: fasting blood sugar was 15.6. After taking the hypoglycemic composition prepared in Example 2 of the present invention, blood sugar dropped to 11 in less than 1 week (the patient did not control his diet, and follow-up will be conducted to guide the adjustment of the dosage);
[0102] Case 6: Blood sugar level was 15.7 2 hours after meal. After taking the hypoglycemic composition prepared in Example 2 of the present invention, blood sugar level dropped to 14.3 2 hours after meal in less than 3 days (the patient did not control his diet, and follow-up will be conducted to guide the adjustment of dosage).
[0103] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0104] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A hypoglycemic composition, characterized in that: include: Sea buckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, mulberry, sorbitol, magnesium stearate and probiotics.
2. A hypoglycemic composition according to claim 1, characterized in that: The ingredients in proportion by weight include: 3-5 parts of sea buckthorn, 15-20 parts of Jerusalem artichoke, 10-15 parts of ginseng, 5-10 parts of bitter melon, 3-5 parts of polygonatum, 2-4 parts of yam, 5-8 parts of kudzu root, 5-10 parts of wolfberry, 5-10 parts of mulberry, 2-4 parts of sorbitol, 1-3 parts of magnesium stearate and 3-5 parts of probiotics.
3. The hypoglycemic composition according to claim 1, characterized in that The ingredients in proportion by mass include: 4 parts of sea buckthorn, 18 parts of Jerusalem artichoke, 13 parts of ginseng, 7 parts of bitter melon, 4 parts of polygonatum, 3 parts of yam, 7 parts of kudzu root, 10 parts of wolfberry, 8 parts of mulberry, 3 parts of sorbitol, 2 parts of magnesium stearate and 4 parts of probiotics.
4. The method for preparing the hypoglycemic composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) seabuckthorn, Jerusalem artichoke, ginseng, bitter melon, polygonatum, yam, kudzu root, wolfberry, and mulberry are mixed and crushed to obtain a base material; (2) adding water, amylase, lipase and cellulase to the base material for enzymolysis and then killing the enzymes to obtain an enzymolyzate; (3) adding the enzymatic hydrolysate to probiotics for low-temperature fermentation to obtain a fermentation material; (4) Add sorbitol to the fermented material, stir evenly and then dry; finally add magnesium stearate, mix evenly and then press.
5. The preparation method according to claim 4, characterized in that: The crushing in step (1) is performed through a 500-mesh sieve.
6. The preparation method according to claim 5, characterized in that: In step (2), the mass ratio of the base material to water is 1:7-9; the mass ratio of the base material to amylase, lipase and cellulase is 100:1:1-2:1-2; the enzymolysis temperature is 25-40°C and the enzymolysis time is 1-2 days; the enzyme inactivation temperature is 100°C.
7. The preparation method according to claim 6, characterized in that: The low-temperature fermentation in step (3) is at 15-20° C. and the fermentation time is 2-3 days.
8. The preparation method according to claim 7, characterized in that: The drying in step (4) has a water content lower than 10%.
9. Use of the hypoglycemic composition according to any one of claims 1 to 3 in pharmaceuticals and foods.
10. The use according to claim 9, characterized in that The dosage form of the medicine is tablet or pill.
